Previous 10 | Next 10 |
vTv Therapeutics (NASDAQ: VTVT ): Q1 Non-GAAP EPS of -$0.09; GAAP EPS of -$0.26. More news on: vTv Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter that ended March 31, 2019, and provided an update on recent achievements and upcoming events. “We continue to make significant progress with our operational plans and look forward to annou...
Biogen's (BIIG) latest clinical trial failure is a testament to the difficulty in developing drugs for Alzheimer's, which is littered with failures in the last ten years. But other neurology fields have seen major advances recently, one of the leading being with medical devices that use el...
VTv Therapeutics (NASDAQ: VTVT ) is 8.9% higher after hours following its announcement that it will present results at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases in Portugal, which runs through Monday. More news on: vTv Therapeutics Inc., ...
Presentation of Results for Subgroup of Patients with Mild Alzheimer’s Disease and Type 2 Diabetes in the STEADFAST Study vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatment...
Gainers: Dermira (NASDAQ: DERM ) +85% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +48% . Atossa Genetics (NASDAQ: ATOS ) +35% . American Midstream Partners (NYSE: AMID ) +28% . Aclaris Therapeutics (NASDAQ: ACRS ) +21% . Innovate Biopharmaceuticals (NASDAQ: INNT ) +20% . Profess...
Thinly traded vTv Therapeutics slides ( VTVT -14.3% ) as the company enters into an agreement with certain institutional investors for registered direct offering of ~3.6M shares at $1.65/share for gross proceeds of ~$6M More news on: vTv Therapeutics Inc., Healthcare stocks news, ...
Aerpio Pharmaceuticals (NASDAQ: ARPO ) -64% after lead candidate flunks mid-stage study. More news on: Aerpio Pharmaceuticals, Inc., NII Holdings, Inc., PolarityTE, Inc., Stocks on the move, Read more ...
Proceeds Will Fund Start-Up Activities for Current and Future Clinical Trials vTv Therapeutics Inc. (Nasdaq:VTVT) (the “Company”) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale in a registere...
vTv Therapeutics Inc. ( VTVT) is a pharmaceutical company with 7 drug candidates currently in different clinical stages. The programs are mainly focused on Alzheimer’s disease, diabetes, and inflammation. However, its most promising candidate, azeliragon, just failed Phase 3 trial for ...
News, Short Squeeze, Breakout and More Instantly...
vTv Therapeutics Inc. Company Name:
VTVT Stock Symbol:
NASDAQ Market:
vTv Therapeutics Inc. Website:
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has pla...
2024-06-26 16:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed in over ...